⚡ Quick Answer — What is Carvego?
Carvego είναι 6.25 mg carvedilol tablet from a WHO-GMP certified manufacturer — non-selective beta-blocker with additional alpha-1 blockade. Primary use is hypertension; also used for angina, arrhythmia control, post-myocardial-infarction secondary prevention, and heart failure with reduced ejection fraction (HF-REF) (one of the three mortality-proven beta-blockers in HF-REF). Typical hypertension dose: 6.25-25 mg twice daily (12.5-50 mg/day). Contraindicated in asthma, severe bradycardia, second/third-degree heart block, acute decompensated heart failure, and phaeochromocytoma without prior alpha-blockade. Do NOT stop abruptly — taper over 1-2 weeks to avoid rebound tachycardia / angina / MI.
📦 Κάθε παραγγελία καλύπτεται από την Πολιτική Εγγύησης Επαναποστολής — εάν το δέμα σας δεν φτάσει εντός 20 εργάσιμων ημερών, το επαναποστέλλουμε.
Γιατί να παραγγείλετε από τη MedsBase
Τα γενόσημα φάρμακά μας προέρχονται από κατασκευαστές που πιστοποιούνται από την WHO-GMP και αποστέλλονται παγκοσμίως σε διακριτική, απλή συσκευασία — χωρίς όνομα φαρμάκου στο εξωτερικό του δέματος. Οι πληρωμές με κάρτα δρομολογούνται μέσω ρυθμισμένου επεξεργαστή (οι περιγραφές εκκαθάρισης περιλαμβάνουν ρυθμισμένο επεξεργαστή πληρωμών με κάρτα — ποτέ “MedsBase” ή οποιοδήποτε όνομα φαρμάκου). Γίνονται δεκτές και πληρωμές με κρυπτονομίσματα και τραπεζική μεταφορά SEPA. Κάθε παραγγελία καλύπτεται από την Πολιτική Επαναποστολής Εξασφαλίσεώς μας.
What Is Carvego?
Carvego is an oral tablet containing carvedilol 6.25 mg from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Carvedilol is a non-selective beta-blocker with additional alpha-1 blockade. Third-generation beta-blocker with vasodilator properties from alpha-1 blockade. Distinguished by landmark heart-failure evidence (COPERNICUS, CAPRICORN): one of only three beta-blockers (with metoprolol succinate and bisoprolol) proven to reduce mortality in HF-REF.
How Carvedilol Lowers Blood Pressure
Beta-blockers reduce blood pressure through four mechanisms:
- Reduction of cardiac output — beta-1 blockade in the sinoatrial node reduces heart rate, and blockade in ventricular myocardium reduces contractility. Lower cardiac output = lower blood pressure.
- Renin-angiotensin suppression — beta-1 blockade in juxtaglomerular cells reduces renin release, lowering angiotensin II and aldosterone over 2-4 weeks. This accounts for much of the long-term BP effect.
- Central sympathetic reduction — lipophilic beta-blockers cross the blood-brain barrier and reduce central sympathetic outflow.
- Alpha-1 blockade — direct peripheral vasodilation (carvedilol-specific), giving a faster BP reduction than pure beta-blockers.
Beta-blockers are lipophilic. Plasma half-life of carvedilol is 7-10 hours.
Approved and Evidence-Based Uses
- Hypertension (primary indication)
- Heart failure with reduced ejection fraction (HF-REF) — evidence-based, mortality-reducing; titrate from 3.125 mg BID to 25 mg BID (50 mg BID in patients >85 kg) over 8-12 weeks
- Post-MI secondary prevention — CAPRICORN trial
- Stable angina
- Left ventricular dysfunction post-MI
Carvego Dosage
Adult hypertension dose: 6.25-25 mg twice daily (12.5-50 mg/day).
Start low, titrate upward over 2-4 weeks to target BP (typically <140/90 in uncomplicated hypertension; <130/80 in diabetes, chronic kidney disease, or established cardiovascular disease). Check resting pulse before each dose-increase — do not titrate if <55 bpm.
Παρακολούθηση:
- Resting pulse and BP at 2, 4, and 8 weeks after starting or dose change
- Baseline ECG if any cardiac history; periodic ECG if symptoms change
- For HF-REF use: echocardiogram at 3 and 6 months; titrate toward target dose if tolerated
Administration: swallow whole with water. Take at approximately the same time each day.
Discontinuation: NEVER stop abruptly. Taper over 1-2 weeks (reduce by 25-50% every 3-5 days). Abrupt discontinuation causes rebound tachycardia, worsened angina, and — in patients with coronary disease — can precipitate myocardial infarction. This is one of the most important safety points for beta-blockers.
Παρενέργειες
Common (>5%):
- Fatigue, lethargy — often adapts over 2-4 weeks
- Cold hands and feet (peripheral vasoconstriction)
- Bradycardia (check pulse; stop if <50 bpm)
- Exercise intolerance — maximum heart rate is blunted by beta blockade
- Dizziness, postural hypotension
- CNS effects possible but less common than with propranolol
- Postural dizziness (more common due to vasodilator component)
Λιγότερο συχνές: depression, reduced libido / erectile dysfunction, gastrointestinal upset, Raynaud-like cold intolerance, bronchospasm (more common with non-selective agents).
Important but uncommon:
- Masked hypoglycaemia in diabetics — beta-blockers blunt the tachycardia / tremor warning signs of low blood sugar. Monitor glucose more carefully; prefer nebivolol ή bisoprolol in insulin-treated diabetes.
- Bronchospasm — can be severe in asthma / COPD. Absolute contraindication for non-selective agents; relative for cardioselective.
- Heart block or worsening heart failure — in susceptible patients. Start low, titrate slowly.
Contraindications & Cautions
- Asthma / severe COPD / any bronchospastic disorder — absolute contraindication (non-selective beta blockade)
- Second or third-degree atrioventricular block (without pacemaker)
- Sinus bradycardia <50 bpm
- Cardiogenic shock, decompensated heart failure requiring inotropes
- Severe peripheral arterial disease, Raynaud’s syndrome (relative)
- Phaeochromocytoma without prior alpha-blockade — paradoxical hypertensive crisis (Carvedilol has alpha-1 blocker component, which softens but does not eliminate this risk)
- Severe hepatic impairment (for extensively hepatic-metabolised agents: propranolol, metoprolol, carvedilol, labetalol)
- Severe renal impairment — dose adjustment needed for renal-excreted agents (atenolol, nadolol)
- Hypersensitivity to carvedilol
Pregnancy: Category C; cross the placenta; small risk of intrauterine growth restriction, neonatal bradycardia, and hypoglycaemia. Use only if benefit clearly outweighs risk; labetalol is the pregnancy-preferred beta-blocker.
Breastfeeding: small amounts in breast milk; generally considered compatible with monitoring.
Αλληλεπιδράσεις Φαρμάκων
- Verapamil, diltiazem (non-dihydropyridine CCBs) — additive bradycardia, heart block, and negative inotropy; generally avoid combination. Dihydropyridine CCBs (amlodipine, nifedipine) are safer to combine with beta-blockers.
- Other beta-blockers — do not combine; additive bradycardia
- Clonidine — if stopping clonidine, stop the beta-blocker first (several days before) to avoid rebound hypertensive crisis
- Insulin and sulphonylureas — mask hypoglycaemia warning signs; monitor glucose closely
- Μη στεροειδή αντιφλεγμονώδη φάρμακα (NSAIDs) — reduce the antihypertensive effect of beta-blockers; avoid chronic combination
- CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion) — raise carvedilol levels; reduce dose or monitor closely
- Αλκοόλ — additive hypotension and CNS depression (particularly for lipophilic agents)
Beta-Blocker Class at a Glance
| Beta-blocker | Selectivity | Καλύτερο για |
|---|---|---|
| Propranolol (Inderal, Ciplar, Beloc) | Non-selective | Migraine, tremor, thyrotoxicosis, performance anxiety, HTN |
| Metoprolol | Cardioselective | Post-MI, HF-REF (succinate ER), angina, AF rate control |
| Carvedilol | Non-selective + α-1 | HF-REF (mortality evidence), post-MI |
| Bisoprolol | Highly cardioselective | HF-REF, HTN, angina, AF rate control |
| Nebivolol | Ultra-selective + NO | Elderly, metabolic syndrome, erectile dysfunction |
| Atenolol | Cardioselective (hydrophilic) | Angina, AF rate control (second-line for HTN) |
| Labetalol | Non-selective + α-1 | Pregnancy hypertension, hypertensive crisis |
Το 3.125 mg starter strength (Carloc) and 6.25 mg step-up (Carvego) are designed for the gradual HF-REF titration ladder. Non-selective; contraindicated in asthma.
Αποθήκευση
Store Carvego below 25°C. Keep out of reach of children — accidental paediatric beta-blocker ingestion can cause life-threatening bradycardia and hypoglycaemia.
Συχνές Ερωτήσεις
How long does Carvego take to lower blood pressure?
You should see some BP reduction within 1-2 days of starting; the full antihypertensive effect takes 2-4 weeks (driven by the gradual renin-angiotensin suppression, not the immediate heart-rate effect). Measure BP at home at the same time each day to track response.
Can I take Carvego if I have asthma?
No — Carvedilol is non-selective and can cause severe bronchospasm in asthmatics. Absolute contraindication. For asthmatic patients needing a beta-blocker, nebivolol ή bisoprolol (highly cardioselective) are safer alternatives — though no beta-blocker is completely safe in asthma.
Why should I never stop Carvego abruptly?
Abrupt discontinuation causes rebound tachycardia and worsened angina within 24-48 hours, driven by up-regulation of beta receptors during chronic blockade. In patients with coronary artery disease, this can precipitate myocardial infarction or unstable angina. Always taper over 1-2 weeks when stopping.
Will Carvego affect my exercise performance?
Yes — beta blockade blunts the heart-rate response to exercise, so your maximum pulse is lower and you fatigue faster at high intensities. For recreational exercise most people adapt; for competitive endurance athletes, beta-blockers can meaningfully impair performance and are banned in precision sports (shooting, archery — where they reduce physiological tremor).
Will Carvego affect my blood sugar if I have diabetes?
Beta-blockers mask the tachycardia / tremor / palpitation warning signs of hypoglycaemia, making low blood sugar harder to detect. They can also blunt the counter-regulatory glucose response. Monitor glucose more frequently on a beta-blocker, particularly if on insulin or sulphonylureas. Nebivolol και bisoprolol have the best metabolic profile.
Can I drink alcohol on Carvego?
Moderate alcohol is generally acceptable but alcohol potentiates the hypotensive and CNS-depressant effects. Stand up slowly after drinking. Alcohol is also an independent BP-raiser; reducing intake can improve BP control independent of Carvego.
Does Carvego cause weight gain?
Older beta-blockers (propranolol, atenolol, metoprolol) are associated with modest weight gain (1-3 kg) and worsening of insulin sensitivity over time. Nebivolol and carvedilol are weight-neutral or slightly weight-favourable due to their vasodilator components. For patients with metabolic syndrome, nebivolol is the preferred beta-blocker when one is needed.
Is Carvego safe in pregnancy?
Category C. Use only if benefit clearly outweighs risk. For antihypertensive use in pregnancy, labetalol is the preferred beta-blocker; methyldopa and nifedipine are the two other pregnancy-safe options.
Can I take Carvego with other BP medications?
Yes — beta-blockers combine well with dihydropyridine calcium-channel blockers (amlodipine), Αναστολείς ACE (ramipril, lisinopril), ARBs (losartan, telmisartan, olmesartan), and thiazide diuretics (HCTZ). Avoid combination with non-dihydropyridine CCBs (verapamil, diltiazem) — additive bradycardia and heart-block risk.
Where can I buy Carvego online?
You can buy Carvego (carvedilol 6.25 mg tablet, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.
Related Beta-Blockers & Antihypertensives
- Beloc — Propranolol 10/20/40 mg
- Ciplar — Propranolol 10 mg (Cipla)
- Labebet — Labetalol 100 mg (pregnancy-safe)
- Metolar — Metoprolol Tartrate 25/50/100 mg
- Metomac — Metoprolol 25 mg
- P-Nolol — Propranolol 20/40 mg
- Browse all High Blood Pressure Medications
Σχετικές Εναλλακτικές
Άλλα προϊόντα σε Χρόνιες Παθήσεις που οι πελάτες εξετάζουν επίσης:



























Κριτικές
Δεν υπάρχουν ακόμη κριτικές